Skip to main content
main-content

Rheumatoid arthritis

Highlights

14-01-2019 | Rheumatoid arthritis | Highlight | News

Trial results support management of cardiovascular risk factors in RA patients

Managing traditional cardiovascular risk factors with a treat-to-target approach slows progression of subclinical atherosclerosis among patients with rheumatoid arthritis, suggest results from the FRANCIS trial.

Source:

Ann Rheum Dis 2019; doi:10.1136/annrheumdis-2018-214075

20-12-2018 | Rheumatoid arthritis | Highlight | News

Serum calprotectin predicts relapse risk in TNFi-treated RA, PsA

Serum calprotectin levels independently predict relapse risk in tumor necrosis factor inhibitor-treated patients with rheumatoid arthritis or psoriatic arthritis who are in remission or have low disease activity, Spanish researchers report.

Source:

Arthritis Res Ther 2018; doi:10.1186/s13075-018-1764-z

19-12-2018 | Diagnosis and screening | Podcast | Audio

The importance of early diagnosis and treatment of inflammatory arthritis

In this Medicine Matters rheumatology podcast, we talk to President-Elect of EULAR Professor Iain McInnes, about the importance of early diagnosis and treatment of rheumatic diseases.

03-12-2018 | Rheumatoid arthritis | Highlight | News

Chronic opioid use rising in RA patients

Chronic opioid use among patients with rheumatoid arthritis increased substantially between 2002 and 2015, researchers report.

Source:

Arthritis Rheumatol 2018; doi:10.1002/art.40789

15-11-2018 | Etanercept biosimilar | Highlight | News

No worsening in disease activity with switch to biosimilar etanercept

Disease activity does not change following the switch from etanercept to the biosimilar formulation SB4, and treatment retention rates may be determined by patient-specific factors, suggests an analysis of the DANBIO registry.

Source:

Ann Rheum Dis 2018; doi:10.1136/annrheumdis-2018-213474

14-11-2018 | Infection | Editorial | Article

Minimizing infection risk with biologic therapy

While the development of biologics has revolutionized treatment of rheumatic diseases, these agents can lead to immunosuppression and increased infection risk. Eoin Feeney discusses the role of screening and treatment for latent infection prior to therapy, vaccination timing, and travel risks in patients taking these medications.

Author:
Eoin Feeney

29-10-2018 | Rheumatoid arthritis | ACR/ARHP 2018 | News

Peficitinib may be a promising treatment option for RA

Findings from two phase III trials presented at the 2018 ACR/ARHP Annual Meeting in Chicago, Illinois, USA, demonstrate that treatment with the JAK inhibitor peficitinib may be beneficial for patients with rheumatoid arthritis.

Source:

ACR/ARHP Annual Meeting; Chicago, Illinois, USA: 19–24 October 2018

21-10-2018 | Rheumatoid arthritis | ACR/ARHP 2018 | News

High-dose influenza vaccine enhances immune response in RA patients

Administration of a high-dose influenza vaccine results in an improved humoral immune response when given to patients with rheumatoid arthritis, suggest findings from a randomized controlled trial.

Source:

ACR/ARHP Annual Meeting; Chicago, Illinois, USA: 19–24 October 2018 

18-10-2018 | Microbiome | Editorial | Article

Why every rheumatologist should understand the microbiome

James Rosenbaum and Mark Asquith discuss how the microbiome interacts with the immune system, how this may induce inflammation, and how the microbiome could be used as a therapeutic target for rheumatic diseases.

Authors:
James T Rosenbaum, Mark J Asquith

10-10-2018 | Mental health | Editorial | Article

Why depression and anxiety matter in patients with inflammatory arthritis

Advisory Board member Susan Bartlett discusses the prevalence of mental health comorbidities in patients with inflammatory arthritis, and their impact on disease symptoms and quality of life.

Author:
Susan Bartlett

17-09-2018 | Rheumatoid arthritis | Highlight | News

No increased risk for CVD events with tocilizumab over other RA biologic DMARDs

Tocilizumab has a cardiovascular disease risk comparable with that of etanercept and other biologic DMARDs in individuals with rheumatoid arthritis, according to findings from a large, retrospective cohort study using real-world data.

Source:

Arthritis Care Res 2018; doi:10.1002/acr.23737

07-09-2018 | Treatment | Feature | Article

At a glance: Common scores used in rheumatology

A quick-reference guide to the scores that are commonly used in clinical trials and daily rheumatology practice.

06-09-2018 | Pregnancy | Highlight | News

Increased risk for preterm delivery in women with RA and JIA

Women with rheumatoid arthritis and those with juvenile idiopathic arthritis have a significantly elevated risk for preterm delivery, according to a prospective cohort study published in Arthritis Care & Research.

Source:

Arthritis Care Res 2018; doi:10.1002/acr.23730

05-09-2018 | Rheumatoid arthritis | Highlight | News

News in brief

Biosimilar infliximab may not reduce treatment costs for US patients

Using infliximab-dyyb instead of the reference product may not reduce out-of-pocket costs for US rheumatoid arthritis patients insured on the Medicare Part D system, study results suggest.

09-08-2018 | Rheumatoid arthritis | Article

Mediterranean diet and risk of rheumatoid arthritis: A population-based case-control study

Johansson K et al. Arthritis Res Ther 2018; 20: 175. doi: 10.1186/s13075-018-1680-2

20-08-2018 | Rheumatoid arthritis | Highlight | News

Possible link between early life tobacco exposure and RA risk

Researchers have investigated the association between passive exposure to tobacco smoke during childhood and the risk for rheumatoid arthritis later in life.

Source:

Rheumatology 2018; doi:10.1093/rheumatology/key219

14-08-2018 | Rheumatoid arthritis | Highlight | News

TNF inhibitors may not increase cancer recurrence risk

Patients with a history of cancer who receive tumor necrosis factor inhibitors for rheumatoid arthritis may not be at increased risk for recurrence, suggests a Swedish population-based study.

Source:

Ann Intern Med 2018; doi:10.7326/M17-2812

11-07-2018 | Arthroplasty | Review | Article

Total joint arthroplasty in patients with inflammatory rheumatic diseases

Compagnoni R, Gualtierotti R, Randelli P. Adv Ther 2018. doi: 10.1007/s12325-018-0750-9

image credits